F. Hoffmann-La Roche AG said on Thursday its sales in the first quarter of fiscal 2025 reached 15.4 billion Swiss francs, climbing 7% in Swiss francs and 6% at constant exchange rates (CER) from the same period a year earlier.
Sales in the pharmaceuticals division grew 8% at CER to 11.95 billion Swiss francs, while diagnostics division sales amounted to 3.49 Swiss francs, virtually unchanged from the same timeframe in 2024.
"We had a good start to the year with Group sales increasing by 6% at constant exchange rates and we achieved a number of important milestones," CEO Thomas Schinecker commented. "We are expanding our already strong US footprint – with currently over 25,000 employees, 15 R&D and 13 manufacturing sites – by investing USD 50 billion, an important step to continue to meet patient needs in the US with highly innovative medicines and diagnostics," he said.
